Ticilimumab
From Wikipedia, the free encyclopedia
|
Ticilimumab
|
|
|
|
|
| Source | Human |
| Target | ? |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ticilimumab is a fully human monoclonal antibody produced by Pfizer. It binds to the CTLA-4 molecule, which is expressed on the surface of activated T lymphocytes. Ticilimumab is thought to stimulate patients’ immune systems to attack their tumors. Ticilimumab has been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies. See Reuben JM et al., Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006 Jun 1;106 (11):2437-44.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Adalimumab, Adecatumumab, Anetumumab, Atorolimumab, Belimumab, Bertilimumab, Betumumab, Cetforlimumab, Cetinlimumab, Cetlalimumab, Cetolimumab, Cynosumab, Denosumab, Duntumumab, Durimulumab, Durmulumab, Efungumab, Exbivirumab, Futumumab, Genosumab, Golimumab, Intumumab, Ipilimumab, Iratumumab, Lerdelimumab, Lexatumumab, Libivirumab, Mapatumumab, Metelimumab, Nebacumab, Ofatumumab, Panitumumab, Pritumumab, Raxibacumab, Regavirumab, Resatumumab, Restumumab, Rosutumumab, Sevirumab, Stamulumab, Synosumab, Ticilimumab, Tritumumab, Trixatumumab, Tuvirumab, Vexatumumab, Votumumab, Zalutumumab, Zanolimumab, Ziralimumab
